Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Octreotide acetate is stored in the refrigerator between 36 F and 46
F (2 C to 8 C).
It should be stored in its outer carton to protect it from
If stored at room temperature, octreotide acetate is stable for 14 days
if protected from light.
Prior to injection the solution should be allowed to
warm up to room temperature.
The manufacturer recommends against the use of
artificial means to warm up the solution.
Multi-dose vials should be used within
14 days of opening.
Ampuls are intended for single-use only and any unused
portion should be discarded after opening.
Although injection into fatty tissue (subcutaneously) is preferred, octreotide acetate also
can be given by injection into the vein (intravenously).
Hands should be washed before and after administration.
Before injecting, octreotide should be allowed to come to room temperature.
To decrease pain
associated with subcutaneous injection the smallest possible volume to deliver
the drug should be used.
Injection sites should be rotated to decrease injection
If the solution becomes cloudy, has particles, or is leaking, it
should not be used. Used needles should be thrown away in a needle or sharps
Treatment may be started with 50 mcg three times daily. For most patients,
100 mcg three times daily was found to be effective. However, some patients
required up to 500 mcg three times daily.
Carcinoid tumor treatment
To treat symptoms of severe diarrhea and flushing in
patients with metastatic carcinoid tumors, the recommended daily dose of octreotide acetate during the first 2 weeks of
treatment ranges from 100-600 mcg/day in 2-4 divided doses (average daily dose
is 300 mcg).
To treat severe diarrhea associated with VIP-secreting tumors, the recommended daily dose of octreotide acetate during the first 2 weeks of
therapy is 200-300 mcg in 2-4 divided doses (150-700 mcg) to achieve symptom
control. Dose may be adjusted based on individual patient response but usually
doses > 450 mcg/day are not required.